LDBA Stock Overview
A biopharmaceutical company, engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 1/6 |
| Past Performance | 3/6 |
| Financial Health | 5/6 |
| Dividends | 3/6 |
H. Lundbeck A/S Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr.4.92 |
| 52 Week High | kr.5.27 |
| 52 Week Low | kr.4.12 |
| Beta | 0 |
| 1 Month Change | 12.49% |
| 3 Month Change | 10.47% |
| 1 Year Change | -0.57% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 14.57% |
Recent News & Updates
Recent updates
Shareholder Returns
| LDBA | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -0.4% | -0.8% | -0.4% |
| 1Y | -0.6% | -20.1% | 8.6% |
Return vs Industry: LDBA exceeded the German Pharmaceuticals industry which returned -20.1% over the past year.
Return vs Market: LDBA underperformed the German Market which returned 8.6% over the past year.
Price Volatility
| LDBA volatility | |
|---|---|
| LDBA Average Weekly Movement | 3.2% |
| Pharmaceuticals Industry Average Movement | 5.5% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 10.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: LDBA has not had significant price volatility in the past 3 months.
Volatility Over Time: LDBA's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1915 | 5,681 | Charl van Zyl | www.lundbeck.com |
H. Lundbeck A/S, a biopharmaceutical company, engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company’s principal products include Abilify Maintena/Abilify Maintena for schizophrenia and bipolar I disorder in adults; Brintellix/Trintellix to treat depressive disorders; Northera for the treatment of symptomatic neurogenic orthostatic hypotension; Vyepti for migraine prevention; and Rexulti/Rxulti to treat MDD and schizophrenia. It also provides Azilect for treating Parkinson’s disease; Cipralex/Lexapro for depression; Ebixa to treat dementia; Onfi for epilepsy; Sabril for the treatment of refractory complex partial seizures and infantile spasms; Xenazine for chorea; Deanxit for depression; Cipramil for depression and anxiety; and Cisordinol to treat psychosis.
H. Lundbeck A/S Fundamentals Summary
| LDBA fundamental statistics | |
|---|---|
| Market cap | €4.81b |
| Earnings (TTM) | €323.78m |
| Revenue (TTM) | €2.70b |
15.2x
P/E Ratio1.8x
P/S RatioIs LDBA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LDBA income statement (TTM) | |
|---|---|
| Revenue | kr.20.16b |
| Cost of Revenue | kr.4.45b |
| Gross Profit | kr.15.70b |
| Other Expenses | kr.13.29b |
| Earnings | kr.2.42b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 21, 2024
| Earnings per share (EPS) | 2.44 |
| Gross Margin | 77.91% |
| Net Profit Margin | 11.99% |
| Debt/Equity Ratio | 16.6% |
How did LDBA perform over the long term?
See historical performance and comparison